scispace - formally typeset
E

Esmat Abdi

Researcher at University of Mohaghegh Ardabili

Publications -  17
Citations -  232

Esmat Abdi is an academic researcher from University of Mohaghegh Ardabili. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 7, co-authored 14 publications receiving 131 citations. Previous affiliations of Esmat Abdi include Ardabil University of Medical Sciences.

Papers
More filters
Journal ArticleDOI

Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives

TL;DR: It is shown that GC family history, lifestyle, demographics, gastroesophageal reflux disease, Helicobacter pylori infection, and multiple genetic and epigenetic risk factors as well as several predisposing conditions may underlie susceptibility to CGA.
Journal ArticleDOI

Entrapment of uropathogenic E. coli cells into ultra-thin sol-gel matrices on gold thin films: A low cost alternative for impedimetric bacteria sensing

TL;DR: It is shown here the possibility to imprint the rod-shape structure of E. coli UTI 89 into ultra-thin inorganic silica coatings on gold electrodes in a reproducible manner and brings us closer to a low cost specific bacterial recognition surfaces.
Journal ArticleDOI

Helicobacter pylori genotypes determine risk of non-cardia gastric cancer and intestinal- or diffuse-type GC in Ardabil: A very high-risk area in Northwestern Iran.

TL;DR: It is proposed that the new types of H. pylori vacA, i1 and d1, might be important determinants of NCGC risk in Ardabil, and the m1, not independently, but in combination might further define the risk of GC.
Journal ArticleDOI

Helicobacter pylori vacuolating cytotoxin genotypes and preneoplastic lesions or gastric cancer risk: a meta-analysis.

TL;DR: The strength of this association in adult‐infected populations is examined and the impact of mean age‐standardized incidence rates (ASRs) of GC as a hypothesized moderator variable is modeled.
Journal ArticleDOI

Emerging circulating MiRNAs and LncRNAs in upper gastrointestinal cancers

TL;DR: The potential clinical application of emerging circulating miRNAs and lncRNAs in upper GI cancers are comprehensively reviewed and different clinical trials and large, multi-center cohorts as well as comprehensive meta-analyses are conducted to validate and use emerging circulating ncRNAs as the indicators of GI cancers.